Umbilical cord blood T lymphocyte (UCB T cell)

T cells from the unmanipulated cord blood fraction represent the endogenous T lymphocyte population found in umbilical cord blood (UCB) that has not been subjected to ex vivo processing such as expansion or genetic engineering (Ballen et al., 2013, Blood). These cells are distinct from adult peripheral blood T cells due to their predominantly naive state, characterized by high expression of CD45RA and a lack of prior antigen exposure (Hiwarkar et al., 2015, Blood). This naive status contributes to a lower incidence and severity of graft-versus-host disease (GVHD) in the recipient, even in the presence of human leukocyte antigen (HLA) mismatches, making UCB a viable source for hematopoietic stem cell transplantation (Rocha et al., 2000, Bone Marrow Transplantation). Despite their immaturity, these T cells are capable of mounting potent immune responses and providing a graft-versus-leukemia (GVL) effect, which is essential for preventing disease relapse in cancer patients (Merindol et al., 2011, Immunotherapy). However, the low absolute number of T cells in a single cord blood unit can lead to delayed immune reconstitution and an increased risk of opportunistic infections post-transplant (Komanduri et al., 2007, Biology of Blood and Marrow Transplantation). In clinical practice, these cells are often compared to manipulated fractions to optimize the balance between GVL and GVHD. They serve as the primary adaptive immune component in cord blood transplants used to treat various leukemias and lymphomas. Their functional capacity is also being explored in the development of third-party virus-specific T cell banks.

Other names

Unmanipulated cord blood T cellsCord blood T-cellsUCB T cellsNaive cord blood T cells

Immunosuppressive drugs typically inhibit T cell activation and proliferation by interfering with calcineurin signaling, IL-2 production, or DNA synthesis to prevent or treat graft-versus-host disease.